Table 1 Baseline characteristics of subjects
From: Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer’s subjects?
Age, years | 71.8 ± 7.0 |
Gender, M/F | 80/50 |
BMI, kg/m2 | 25.9 ± 4.3 |
Plasma glucose, mmol/L | 4.9 ± 0.5 |
Plasma insulin, mIU/L | 8.4 ± 7.3 |
HbA1c, mmol/mol | 37.1 ± 6.6 |
HOMA2, mass units | 1.1 ± 0.9 |
HOMA2%β | 98.6 ± 63.5 |
HOMA2%S | 147.6 ± 105.1 |
Total serum cholesterol, mmol/L | 4.9 ± 1.3 |
LDL cholesterol, mmol/L | 2.9 ± 1.0 |
HDL cholesterol, mmol/L | 1.7 ± 0.6 |
Serum triglycerides, mmol/L | 1.6 ± 0.8 |
On treatment with AchE-I (% of total) | 82.9 |
On treatment with antidepressants (% of total) | 25.5 |
MMSE | 24.1 ± 3.1 |
CDR-SoB | 3.6 ± 1.8 |
ADAS-Cog | 31.9 ± 9.9 |
GDS | 5.5 ± 4.7 |
ADCS—ADL | 66.6 ± 9.1 |
COWAT average (total acceptable words) | 10.2 ± 4.8 (30.1 ± 13.6) |
Category fluency test (animals) | 10.6 ± 5.1 |
NPI | 9.6 ± 11.6 |
NPI—caregiver distress | 5.0 ± 6.1 |
Anterior cingulate rCMRGlc, μmol/g/min | 0.27 ± 0.05 |
Posterior cingulate rCMRGlc, μmol/g/min | 0.30 ± 0.05 |
Frontal lobe rCMRGlc, μmol/g/min | 0.31 ± 0.05 |
Temporal lobe rCMRGlc, μmol/g/min | 0.23 ± 0.04 |
Parietal lobe rCMRGlc, μmol/g/min | 0.26 ± 0.05 |
Occipital lobe rCMRGlc, μmol/g/min | 0.28 ± 0.05 |
Medial Temporal lobe rCMRGlc, μmol/g/min | 0.19 ± 0.03 |
Hippocampal rCMRGlc, μmol/g/min | 0.19 ± 0.03 |
Thalamus rCMRGlc, μmol/g/min | 0.25 ± 0.05 |
Striatum rCMRGlc, μmol/g/min | 0.30 ± 0.05 |
Hippocampal volume, mm3 | 3062.2 ± 458.6 |
White matter lesions volume, ml | 6.79 ± 7.7 |
Total grey matter volume, mm3 | 556,401.9 ± 52,622.8 |